Takeda Pharmaceutical (TAK) Competitors $14.74 -0.45 (-2.99%) Closing price 03:59 PM EasternExtended Trading$14.92 +0.18 (+1.21%) As of 04:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock TAK vs. SNY, GSK, ARGX, ONC, BNTX, TEVA, SMMT, ITCI, GMAB, and RDYShould you be buying Takeda Pharmaceutical stock or one of its competitors? The main competitors of Takeda Pharmaceutical include Sanofi (SNY), GSK (GSK), argenx (ARGX), Beigene (ONC), BioNTech (BNTX), Teva Pharmaceutical Industries (TEVA), Summit Therapeutics (SMMT), Intra-Cellular Therapies (ITCI), Genmab A/S (GMAB), and Dr. Reddy's Laboratories (RDY). These companies are all part of the "pharmaceutical products" industry. Takeda Pharmaceutical vs. Sanofi GSK argenx Beigene BioNTech Teva Pharmaceutical Industries Summit Therapeutics Intra-Cellular Therapies Genmab A/S Dr. Reddy's Laboratories Sanofi (NASDAQ:SNY) and Takeda Pharmaceutical (NYSE:TAK) are both large-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, valuation, dividends, community ranking, risk, profitability, media sentiment, analyst recommendations and institutional ownership. Which has more risk & volatility, SNY or TAK? Sanofi has a beta of 0.58, suggesting that its share price is 42% less volatile than the S&P 500. Comparatively, Takeda Pharmaceutical has a beta of 0.39, suggesting that its share price is 61% less volatile than the S&P 500. Does the MarketBeat Community prefer SNY or TAK? Takeda Pharmaceutical received 51 more outperform votes than Sanofi when rated by MarketBeat users. However, 60.24% of users gave Sanofi an outperform vote while only 57.06% of users gave Takeda Pharmaceutical an outperform vote. CompanyUnderperformOutperformSanofiOutperform Votes5060.24% Underperform Votes3339.76% Takeda PharmaceuticalOutperform Votes10157.06% Underperform Votes7642.94% Is SNY or TAK a better dividend stock? Sanofi pays an annual dividend of $1.47 per share and has a dividend yield of 2.7%. Takeda Pharmaceutical pays an annual dividend of $0.53 per share and has a dividend yield of 3.5%. Sanofi pays out 59.0% of its earnings in the form of a dividend. Takeda Pharmaceutical pays out 132.5% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Do analysts rate SNY or TAK? Sanofi currently has a consensus target price of $62.50, suggesting a potential upside of 14.43%. Given Sanofi's higher probable upside, equities research analysts plainly believe Sanofi is more favorable than Takeda Pharmaceutical.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Sanofi 0 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 2 Strong Buy rating(s) 3.00Takeda Pharmaceutical 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has higher valuation & earnings, SNY or TAK? Sanofi has higher earnings, but lower revenue than Takeda Pharmaceutical. Sanofi is trading at a lower price-to-earnings ratio than Takeda Pharmaceutical, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSanofi$44.29B3.13$6.02B$2.4921.94Takeda Pharmaceutical$4.58T0.01$994.06M$0.4037.96 Is SNY or TAK more profitable? Sanofi has a net margin of 12.77% compared to Takeda Pharmaceutical's net margin of 4.53%. Sanofi's return on equity of 25.61% beat Takeda Pharmaceutical's return on equity.Company Net Margins Return on Equity Return on Assets Sanofi12.77% 25.61% 14.72% Takeda Pharmaceutical 4.53%9.39%4.53% Does the media prefer SNY or TAK? In the previous week, Sanofi had 23 more articles in the media than Takeda Pharmaceutical. MarketBeat recorded 29 mentions for Sanofi and 6 mentions for Takeda Pharmaceutical. Sanofi's average media sentiment score of 1.15 beat Takeda Pharmaceutical's score of 0.55 indicating that Sanofi is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sanofi 16 Very Positive mention(s) 5 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Takeda Pharmaceutical 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Do institutionals & insiders have more ownership in SNY or TAK? 14.0% of Sanofi shares are owned by institutional investors. Comparatively, 9.2% of Takeda Pharmaceutical shares are owned by institutional investors. 1.0% of Sanofi shares are owned by company insiders. Comparatively, 0.0% of Takeda Pharmaceutical shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. SummarySanofi beats Takeda Pharmaceutical on 15 of the 19 factors compared between the two stocks. Remove Ads Get Takeda Pharmaceutical News Delivered to You Automatically Sign up to receive the latest news and ratings for TAK and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TAK vs. The Competition Export to ExcelMetricTakeda PharmaceuticalPharmaceutical IndustryMedical SectorNYSE ExchangeMarket Cap$47.66B$6.72B$5.53B$18.93BDividend Yield3.59%2.79%4.86%3.79%P/E Ratio37.966.9923.2231.59Price / Sales0.01198.60363.0825.45Price / Cash4.2765.6738.1617.54Price / Book0.995.926.494.36Net Income$994.06M$142.37M$3.21B$1.02B7 Day Performance0.86%-7.24%-4.91%-3.87%1 Month Performance2.15%-10.45%-0.08%-4.82%1 Year Performance12.61%-14.58%6.40%0.29% Takeda Pharmaceutical Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TAKTakeda Pharmaceutical2.3685 of 5 stars$14.74-3.0%N/A+12.2%$46.89B$4.58T36.8447,300Analyst UpgradeNews CoverageHigh Trading VolumeSNYSanofi3.5124 of 5 stars$55.46-0.6%$62.50+12.7%+13.9%$140.75B$44.29B22.2791,600Analyst RevisionPositive NewsGSKGSK2.995 of 5 stars$38.81+0.2%$43.25+11.4%-6.1%$80.33B$31.38B24.4190,100Gap DownARGXargenx2.9437 of 5 stars$591.87+0.5%$687.00+16.1%+48.1%$35.96B$2.19B-672.58650Positive NewsGap DownONCBeigene2.0481 of 5 stars$272.17+1.8%$310.00+13.9%N/A$26.85B$3.81B-33.0310,600Insider TradeNews CoverageGap UpBNTXBioNTech2.6669 of 5 stars$91.06-4.1%$143.73+57.8%+1.4%$21.85B$2.75B-43.363,080Analyst ForecastAnalyst RevisionGap DownHigh Trading VolumeTEVATeva Pharmaceutical Industries2.2156 of 5 stars$15.39+2.0%$23.43+52.3%+5.1%$17.44B$16.54B-10.6136,800Analyst UpgradeShort Interest ↑Analyst RevisionGap DownSMMTSummit Therapeutics2.6374 of 5 stars$19.29-5.1%$35.44+83.7%+378.7%$14.23B$700,000.00-68.89110Gap DownITCIIntra-Cellular Therapies3.4662 of 5 stars$131.92+0.1%$106.08-19.6%N/A$14.05B$680.50M-151.63560Analyst ForecastNews CoveragePositive NewsGMABGenmab A/S3.879 of 5 stars$19.58-1.6%$41.33+111.1%-34.3%$12.96B$21.53B11.251,660Analyst DowngradeGap DownRDYDr. Reddy's Laboratories3.249 of 5 stars$13.19-0.1%$17.00+28.9%-9.5%$11.01B$311.31B21.0024,800Positive NewsGap Down Remove Ads Related Companies and Tools Related Companies SNY Competitors GSK Competitors ARGX Competitors ONC Competitors BNTX Competitors TEVA Competitors SMMT Competitors ITCI Competitors GMAB Competitors RDY Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:TAK) was last updated on 4/4/2025 by MarketBeat.com Staff From Our PartnersURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredFeds Just Admitted It—They Can Take Your CashThe Government Just Said Your Money Isn't Yours That's right—According to the DOJ, YOUR hard-earned money i...Priority Gold | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredUrgent Bitcoin alert for RIGHT NOWFormer billion-dollar hedge fund manager Larry Benedict has released the most incredible presentation of his 4...Brownstone Research | SponsoredTrump’s Secret WeaponPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredTrump Makes Major Crypto AnnouncementTrump Ends the “War on Crypto” I expect it to pump the market, which is why I'm recommending ONE coin to al...Crypto 101 Media | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredYour Retirement Is Caught in the CrossfireWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Takeda Pharmaceutical Company Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Takeda Pharmaceutical With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
